Kim Ellison

1.5k total citations
26 papers, 1.1k citations indexed

About

Kim Ellison is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kim Ellison has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Kim Ellison's work include Lung Cancer Research Studies (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Kim Ellison is often cited by papers focused on Lung Cancer Research Studies (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Kim Ellison collaborates with scholars based in United States, Japan and China. Kim Ellison's co-authors include Christopher J. Rivard, Leslie Rozeboom, Hui Yu, Yayi He, Fred R. Hirsch, Rafał Dziadziuszko, Kenichi Suda, Fred R. Hirsch, Michael J. Ellison and Shengxiang Ren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Kim Ellison

24 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kim Ellison United States 17 677 414 316 255 148 26 1.1k
Mei‐Kuang Chen United States 12 912 1.3× 527 1.3× 348 1.1× 191 0.7× 131 0.9× 24 1.2k
Hiep Phuc Dong Norway 18 380 0.6× 327 0.8× 283 0.9× 183 0.7× 177 1.2× 33 928
Kavitha Balaji United States 9 381 0.6× 320 0.8× 229 0.7× 142 0.6× 105 0.7× 15 829
Jacinth Wing‐Sum Cheu Hong Kong 10 296 0.4× 383 0.9× 233 0.7× 227 0.9× 287 1.9× 14 829
Christine Alewine United States 18 517 0.8× 295 0.7× 395 1.3× 299 1.2× 97 0.7× 51 1.1k
Desheng Weng China 20 466 0.7× 662 1.6× 353 1.1× 164 0.6× 189 1.3× 59 1.2k
Carol M. Amato United States 16 368 0.5× 616 1.5× 268 0.8× 101 0.4× 327 2.2× 34 1.0k
Abhijit Aithal United States 12 372 0.5× 428 1.0× 218 0.7× 94 0.4× 163 1.1× 23 809
Lisa Cucolo United States 3 668 1.0× 345 0.8× 585 1.9× 114 0.4× 104 0.7× 4 1.0k
Yi Zeng China 14 442 0.7× 285 0.7× 289 0.9× 56 0.2× 164 1.1× 27 802

Countries citing papers authored by Kim Ellison

Since Specialization
Citations

This map shows the geographic impact of Kim Ellison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim Ellison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim Ellison more than expected).

Fields of papers citing papers by Kim Ellison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim Ellison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim Ellison. The network helps show where Kim Ellison may publish in the future.

Co-authorship network of co-authors of Kim Ellison

This figure shows the co-authorship network connecting the top 25 collaborators of Kim Ellison. A scholar is included among the top collaborators of Kim Ellison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim Ellison. Kim Ellison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pozdeyev, Nikita, Timothy A. Erickson, Lian Zhang, et al.. (2020). Comprehensive Immune Profiling of Medullary Thyroid Cancer. Thyroid. 30(9). 1263–1279. 39 indexed citations
3.
Suda, Kenichi, Isao Murakami, Hui Yu, et al.. (2018). CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics. 17(10). 2257–2265. 39 indexed citations
4.
Ren, Shengxiang, Hui Yu, Christopher J. Rivard, et al.. (2018). The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. Lung Cancer. 125. 115–120. 38 indexed citations
5.
6.
Krishnamurthy, Anuradha, Arvind Dasari, Anne M. Noonan, et al.. (2018). Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Research. 78(18). 5398–5407. 24 indexed citations
7.
Suda, Kenichi, Leslie Rozeboom, Christopher J. Rivard, et al.. (2017). Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 109. 1–8. 26 indexed citations
8.
He, Yayi, Hui Yu, Leslie Rozeboom, et al.. (2017). LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology. 12(5). 814–823. 215 indexed citations
9.
Suda, Kenichi, Hui Yu, Kim Ellison, et al.. (2017). Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS ONE. 12(2). e0172209–e0172209. 9 indexed citations
10.
Suda, Kenichi, Isao Murakami, Hui Yu, et al.. (2017). Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. Journal of Thoracic Oncology. 12(6). 1015–1020. 19 indexed citations
11.
He, Yayi, Leslie Rozeboom, Christopher J. Rivard, et al.. (2017). MHC class II expression in lung cancer. Lung Cancer. 112. 75–80. 89 indexed citations
12.
Suda, Kenichi, Leslie Rozeboom, Christopher J. Rivard, et al.. (2017). MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer. Journal of Thoracic Oncology. 12(1). S433–S434. 1 indexed citations
13.
Suda, Kenichi, Leslie Rozeboom, Koh Furugaki, et al.. (2017). Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International. 2017. 1–7. 12 indexed citations
14.
Yu, Hui, Yayi He, Christopher J. Rivard, et al.. (2016). PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines. Journal of Thoracic Oncology. 11(11). S281–S281. 1 indexed citations
15.
Suda, Kenichi, Isao Murakami, Hui Yu, et al.. (2016). Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. Journal of Thoracic Oncology. 11(10). 1711–1717. 12 indexed citations
16.
He, Yayi, Christopher J. Rivard, Leslie Rozeboom, et al.. (2016). Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer. Cancer Science. 107(9). 1193–1197. 151 indexed citations
17.
He, Yayi, Hui Yu, Rafał Dziadziuszko, et al.. (2016). LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients.. Journal of Clinical Oncology. 34(15_suppl). 3039–3039. 1 indexed citations
18.
Zhang, Ping, Hui Yu, A. Badzio, et al.. (2015). Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(7). 1083–1090. 29 indexed citations
19.
Ellison, Kim, Peng Wang, & Grant McFadden. (1996). Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability. Journal of Virology. 70(11). 7965–7973. 36 indexed citations
20.
Ellison, Kim, et al.. (1992). Expression of a ubiquitin derivative that conjugates to protein irreversibly produces phenotypes consistent with a ubiquitin deficiency.. Journal of Biological Chemistry. 267(13). 8807–8812. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mei‐Kuang Chen Breakdown of academic impact, for papers by Hiep Phuc Dong Breakdown of academic impact, for papers by Kavitha Balaji Breakdown of academic impact, for papers by Jacinth Wing‐Sum Cheu Breakdown of academic impact, for papers by Christine Alewine Breakdown of academic impact, for papers by Desheng Weng Breakdown of academic impact, for papers by Carol M. Amato Breakdown of academic impact, for papers by Abhijit Aithal Breakdown of academic impact, for papers by Lisa Cucolo Breakdown of academic impact, for papers by Yi Zeng
Rankless by CCL
2026